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Several preparations of standard immunoglobulins for intravenous use have been tested
as adjunctive therapy for bacterial infections in premature neonates and in critically ill
adults after major surgery, trauma, and burn. The use of intravenous immunoglobulins
in these settings is controversial because the efficacy and cost-effectiveness of this treat-
ment are still not definitivelyestablished. Specificpreparations of immunoglobulins against
Pseudomonas aeruginosa for intramuscular administration have shown promising effi-
cacy, and 'preparations for intravenous administration are now under investigation.
Cross-protection against a wide range of gram-negative infections has been attempted
by the administration of antiserum to the core glycolipid of lipopolysaccharide prepared
from volunteers immunized with the J5 mutant of Escherichia coli 0111. Treatment with
this preparation improved the survival rate of patients with gram-negative bacteremia and,
when administered prophylactically to high-risk surgical patients, prevented shock and
death related to gram-negative infections. The mechanism of protection of the J5 antise-
rum is not clearly understood because of our inability to measure the actual protective
antibody in polyclonal J5 antiserum. Thus, the preparation of readily available cross-
protective hyperimmune immunoglobulins is hampered because there is presently no
method of selecting appropriate donors or high-titered plasma pools.
Passive immunotherapy has been used since 1893
when Behring et al. described the administration of
immune horse serum for the treatment of a patient
with diphtheria [1].Administration of immune horse
serum has since been attempted for the treatment
of many other infections. Although this therapy was
sometimes successful in the treatment of bacterial
infections, it has been largely replaced by antibiotic
therapy. At present, the only established uses for pas-
sive immunotherapy in the field of infectious dis-
eases are as replacement therapy in primary humoral
immunodeficiencies and as prophylaxis for some vi-
ral infections and diseases caused by bacterial exo-
toxins (table 1).
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We now realize that antibiotics have their limita-
tions, especially in the treatment of infectious dis-
eases in critically ill patients. Despite the availabil-
ity of increasingly potent antimicrobial drugs,
bacterial infections remain a major cause of death
in these patients. Adjunctive therapies, such as im-
munoprophylaxis or immunotherapy, are inves-
tigated to improve the outcome of treatment in crit-
ically ill patients. Infections occurring in these
patients are most often acute and unexpected. Fur-
thermore, the patients' underlying diseasesoften pre-
clude the production of sufficient quantities of an-
tibody, even after active immunization. Thus
immunotherapy consists mainly of the administra-
tion of preformed antibodies, either in the form of
immune serum or plasma or in the form of standard
or hyperimmune purified immunoglobulins.
This review discusses the advantages and disad-
vantages of administration of these various forms
of antibody to critically ill patients. We will focus
on some aspects of passive immunotherapy and
mainly on the controversial issues of the passive im-
munologic approach to treatment of bacterial infec-
tions in neonates and surgical patients at high risk
of infection, patients with severeburns, and patients
with established gram-negative bacteremia.
Hyperimmune
Passive Immunotherapy
Table 1. Established indications for the use of immuno-
globulins in the prevention or treatment of infectious
diseases.
Type of
immunoglobulin Indications for use
Standard Prophylaxis and treatment of infection in
primary humoral immunodeficiencies
Prophylaxis of hepatitis A infection
Prophylaxis of measles
Prophylaxis of viral infections
Cytomegalovirus
Hepatitis B
Rabies
Vaccinia
Varicella
Prophylaxis of diseases caused by
bacterial exotoxins
Tetanus
Diphtheria
Botulism*
* Available only as horse serum.
Relation Between Outcome of Infection in the
Critically III Patient and Levels of
Antibody to Bacteria
The role of humoral immunity in host defenses
against bacterial infections is wellknown [2]. In crit-
ically ill patients admitted to intensive care units, the
major causes of infection and death are gram-neg-
ative bacteria [3-6]. Many of the toxic manifesta-
tions induced by gram-negative bacterial infections
are believed to be mediated by the lipopolysaccha-
ride (LPS, endotoxin) component of the outer mem-
brane of these bacteria. Antibiotics are unable to pre-
vent the toxic effects of LPS and may even promote
the release of LPS from bacteria [7].
The importance of antibodies to LPS in the de-
fense against gram-negative infections has been es-
tablished clinically by studies relating the outcome
of infections in patients to titers of specific and cross-
reactive antibodies at the onset of gram-negative bac-
teremia. Antibodies directed against the 0 antigens,
the external part of the LPS, are strain specific. In
contrast, antibodies directed against the core glyco-
lipid, the central part of the LPS, may be cross-re-
active, sincemany determinants of the core glycolipid
are common among gram-negative bacteria.
Antibodies to the core glycolipid may be measured
by use of LPS from rough mutants of gram-negative
bacteria that are unable to incorporate the strain-
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Table 2. Relation of shock and death (S + D) to anti-
body titers in patients with gram-negative bacteremia.
No. of
patients with
Antibody measured Antibody S+ D/total P
(method of detection) titer no. (%) value
Type-specific antibodies*
IgG to 0 antigens (IF) <1:80 63/96 (66)
<.001
>1:80 32/92 (35)
(Indirect HA)t <1:64 19/29 (66)
<.01.
>1:64 54/139 (39)
Cross-reactive antibodiesl
(Indirect HA) <1:80 67/112 (60)
<.01
>1:80 6/39 (15)
NOTE. Adapted from [8] and [11]. Abbreviations: IF =
immunofluorescence; HA = hemagglutination.
* Type-specific antibodies are directed to the side chains of
gram-negative bacterial outer-membrane lipopolysaccharides
(LPS) called 0 antigens, which are strain-specific.
t Indirect hemagglutination measures mainly IgM.
t Cross-reactive antibodies are directed to the core region of
LPS, which is highly conserved among gram-negative bacteria.
LPS of the rough mutant Re of Salmonella minnesota was used
as the antigen to detect antibodies to the core.
specific 0 side chains into the common core region
because they lack the specific enzymes. Thus, the
LPS of these mutants is composed only of lipid A
and various core sugars. Tworough strains have been
widely used to detect cross-reactive antibodies in pa-
tients; one of these is the Re mutant of Salmonella
minnesota used by McCabe et al. [8] and the other
is the 15 mutant of Escherichia coli 0111 used by Pol-
lack et al. [9, 10]. McCabe et al. [8] have shown that
the survival of patients with gram-negative bacter-
emia was related to their titers of antibody to the
core glycolipid present at the onset of bacteremia (ta-
ble 2). The correlation that was found between anti-
body to core glycolipid and survival was indepen-
dent of the levels of b-specific IgG antibody [11].
In addition, these authors found that antibody to
O-specific antigens also correlated significantly with
outcome, although less strikingly than the antibody
to core glycolipid. In their first report [8], McCabe
et al. determined antibody titers by indirect hemag-
glutination with LPS extracted from the infecting
bacteria; this method measures mainly IgM antibod-
ies. Subsequently, when measuring antibodies in the
same sera by immunofluorescence, Zinner et al. [11]
found that survival was significantly related to the
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titers of a-specific IgG antibodies but not to the titers
of a-specific IgM antibodies.
Studies by Pollack et al. [9, 10] have concentrated
on patients with Pseudomonas aeruginosa septice-
mia. In accordance with the observation by McCabe
et al. [8], Pollack and Young [9] observed a similar
relation between survival of patients with R aerugi-
nosa septicemia and titers of a-specific antibodies
measured by indirect hemagglutination with puri-
fied R aeruginosa LPS. A similar correlation was
subsequently found between antibodies to core
glycolipid measured by ELISA and outcome from
R aeruginosa septicemia (table 3) [10]. Both IgG and
IgM antibodies to core glycolipid were associated
with a lower mortality rate. In a multivariate analy-
sis strain-specific hemagglutinating antibody levels
werethe best predictor of outcome, followed by IgM
and then IgG antibodies to core glycolipid.
These observations suggested, therefore, that
strain-specific as well as cross-reactive antibodies
may protect patients from severe septic shock or
death due to gram-negative bacteria. Thus passive
immunotherapy in critically ill patients may be of
benefit. Twoapproaches to passive immunotherapy
have been taken. The first consists of the adminis-
tration of purified immunoglobulins prepared from
pooled plasma from a large number of donors and
containing a wide range of strain-specific antibod-
Table 3. Relation of survival to antibody levels in 43
patients with Pseudomonas aeruginosa septicemia.
Antibody measured Antibody Percent P
(method of detection) levels" survival value
Type-specific antibodiest
(Indirect HA)t ~1:32 48
.03
>1:32 85
Cross-reactive antibodies
IgG Antibody to 15 core
glycolipid (ELISA) <10 14
<.001
>10 79
IgM Antibody to 15 core
glycolipid (ELISA) <30 44
.01
>30 81
NOTE. Adapted from [9] and [10]. Abbreviation: HA =
hemagglutination.
• Antibody levels are expressed as titers for type-specific anti-
bodies and ug/rnl for cross-reactive antibodies.
t For explanations of type-specific and cross-reactive anti-
bodies, see footnotes to table 2: In this experiment lipopoly-
saccharide of the rough mutant 15 of Escherichia coli 0111 was
used as antigen to measure antibodies to the core glycolipid.
t Indirect hemagglutination measures mainly IgM.
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ies. The second approach is the administration of
cross-reactive antibodies.
Rationale for the Use of Purified Intravenous
Immunoglobulin Preparations
Advantages ofimmunoglobulin preparationsfor
intravenous use. Since the 1940s, cold alcohol pre-
cipitation has been used for separating the antibody
(y-globulin) fraction of plasma [12]. This procedure
yields 90% IgG with traces of IgA and IgM. These
preparations contain aggregate forms of IgG that ac-
tivate the complement system when administered in-
travenously and cause a high incidence of untoward
reactions; thus the intramuscular administration of
these preparations is mandatory. The maximum ad-
missible dose by this route is 1.5-3 g per injection,
and absorption is slow, precluding the use of these
immunoglobulin preparations for the treatment of
acute severe infections.
New techniques were developed in the late 1970s
that allow iv administration of immunoglobulin.
Various preparations are now commerciallyavailable,
so that high doses of IgG may be administered in
a small volume with immediate bioavailability. Be-
cause modern blood banks utilize mainly the cellu-
lar components of blood, the supply of plasma de-
rivatives is abundant. Plasmas from thousands of
donors are pooled for preparing purified im-
munoglobulin. Since the immunoglobulin prepara-
tion contains the antibodies present in the pool, it
has high titers of antibody against hundreds of bac-
terial strains [13-15]. Immunoglobulins for intrave-
nous administration (IVIG) have a good opsonic ac-
tivity against various bacteria [16, 17] and have been
shown to be protective against various infections in
animals [15, 18-23]. The storage in lyophilized form
makes IVIG availableon a large scale. These develop-
ments produced renewed interest in the utilization
of purified immunoglobulin for the prophylaxis and
treatment of bacterial infections in critically ill pa-
tients [24].
Controversial aspects of IVIG preparations.
There are some disadvantages of IVIG preparations.
First, the preparation procedures may alter some IgG
functions. The precipitation with ethanol induces a
partial denaturation of the immunoglobulin, which
leads to formation of aggregates and complement
activation. Additional procedures are necessary to
remove the aggregates and to decrease the anticom-
plementary activity. Treatments with pepsin, plas-
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min, p-propiolactone, polyethylene glycol, sulfona-
tion, reduction and alkylation; or treatment with
small doses of pepsin at low pH (e.g., pH 4) may
be used [25]. These procedures induce modifications
of the immunoglobulin molecules in addition to
those induced by the ethanol precipitation. The func-
tional importance of these changes in the clinical set-
ting is not known, but in vitro observations have sug-
gested that some of these procedures may alter the
opsonic activity of the immunoglobulin [16].
A second disadvantage of the use of IVIG prepa-
rations is that some patients lack immune factors
other than IgG. Low levels of plasma IgG in criti-
cally ill patients may be due to conditions such as
increased catabolism, capillary leakage, dilution by
resuscitation regimens, and decreased synthesis due
to lack of nutritional support [26]. However, com-
plex immunologic alterations have been observed af-
ter conditions such as surgery, accidental injuries,
or burns. Neutrophil functions, cell-mediated immu-
nity, complement factors, plasma fibronectin, and
IgM levels may be altered. The relative importance
of these host-defense defects in promoting severein-
fections in critically ill patients is not known. Ad-
ministration of IgG by purified IVIG may therefore
bring only a partial benefit, if any at all, to these
patients.
The third controversial aspect is that largeamounts
of IVIG may block the reticuloendothelial system,
a property that has been used to reduce the clear-
ance of circulating platelets in refractory idiopathic
thrombocytopenia [27]. In patients with infections
such a blockade could be detrimental because of a
decrease in the clearance of circulating microbial
pathogens [28].
For all these reasons carefully planned and con-
ducted clinical trials appear mandatory for explor-
ing the efficacy of IVIG in the treatment of infec-
tions in critically ill patients.
Clinical Studies of IVIG Administration in
Critically III Patients
Neonates. Neonates, particularly when born be-
fore term, are susceptible to bacterial infections be-
cause they have immature immune defenses. Neu-
trophils may exhibit defects in chemotaxis, phago-
cytosis, and killing. Complement levels in newborns
are lower than those in infants and adults. Immu-
noglobulins in neonates consist mainly of IgG trans-
mitted by the mother through the placenta at the end
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of the pregnancy. Premature babies have a deficiency
of IgG because only a small amount of antibody
crosses the placenta early in pregnancy [29].
Group B streptococci are a major cause of neo-
natal sepsis and meningitis [30]. Opsonization and
killing of these encapsulated bacteria are antibody
dependent. Undetectable or low levels of type-
specific antibodies to group B streptococci correlate
with susceptibility to infection with this organism
[31]. Various IVIG preparations have been shown to
have functional activity against group B streptococci
in vitro and in animal experiments [20-23]. These
findings suggest, therefore, that IVIG could be ef-
fective when administered prophylactically to high-
risk neonates or therapeutically to neonates with es-
tablished infections.
Several studies aimed at determining the efficacy
of im-administered immunoglobulin for preventing
infections in neonates have failed to show consistent
benefits [32-34]. Another prophylactic approach
consisting of the administration of IVIG to mothers
with high-risk pregnancies was found to be unfeasi-
ble because very large amounts of IVIG were neces-
sary to cause only a slight increase of IgG levels in
the offspring [35, 36]. Studies using high doses of
IVIG administered to neonates have shown that it
may significantly increase their levelsof IgG, includ-
ing group B streptococcal-specific IgG [35, 37].
However, to the best of our knowledge, no trial of
IVIG for prophylaxis has been performed recently.
A possible protective effect of the therapeutic ad-
ministration of immunoglobulins to newborns in-
fected with group B streptococci was suggested by
a retrospective study showing an improved survival
of infants who received blood containing type-
specific antibody to the infecting group B Strep-
tococcus [38]. In addition, an increased survival of
infants receiving blood transfusions compared with
those not receiving transfusions [39] was reported
in another retrospective study. Clearly these findings
warrant confirmation by prospective studies.
Sidiropoulos et al. [40]have treated 82 neonates -
thought to have bacterial infections - either with an-
tibiotics alone or with antibiotics and a pH 4-treated
IVIG preparation (0.5-1.0 g per day for six days).
Forty-seven infants had clinical signs of sepsis, but
the diagnosis was not confirmed by positive cultures
of blood and CSF. Of the 35 patients with positive
cultures, 20 (nine with E. coli, fivewith Streptococcus
species, three with Klebsiella species, two with
anaerobes, and one with Aerobacter species infec-
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tions) receivedantibiotics and IVIG, and 15(fivewith
E. coli, three with Streptococcus species, two with
Klebsiella species, two with Staphylococcus aureus,
one with Listeria species, one with Serratia species,
and one with Pseudomonas species infections) re-
ceived antibiotics alone. Two of the 20 patients
treated with IVIG died, compared with four of the
15 control patients; this was not a statistically sig-
nificant difference. Within the subgroup of infants
born prematurely, one of 13treated with IVIG and
four of nine control patients died, a difference that
is not statistically significant either by two-tailed y..z
test with Yates' correction or by Fisher's exact test
(the authors found a P value of <.05). This study,
unfortunately, did not provide unequivocal results
because it was not blinded, the number of cases was
small, and the differences were not statistically sig-
nificant.
Burnedpatients. The extensivelyburned patient
is at increased risk of infections as a result of im-
pairment of host-defense mechanisms. R aeruginosa
is particularly troublesome in these patients as it fre-
quently colonizes burned skin. Active immunization
with R aeruginosa vaccine has been studied for al-
most 20 years. These studies have been reviewed else-
where [41].
Serum IgG concentration in burned patients is de-
creased and remains low in fatal cases [42,43]. Ad-
ministration of immunoglobulin by the intramuscu-
lar route has been attempted with variable results.
Kefalides et al. [44] found a significant decrease in
the septic complications of burns by the im adminis-
tration of immunoglobulin. However, the group of
controls had a greater incidence of infectious com-
plications than would be expected and, in addition,
all patients were involved in multiple studies. Stone
et al. [45] could not demonstrate a benefit from the
im administration of a similar amount of immuno-
globulin in 100 patients, a failure attributed to the
minute amounts of antibodies to R aeruginosa con-
tained in the immunoglobulin preparation. Subse-
quent investigators have used im administration of
hyperimmune immunoglobulin against R aeruginosa
with apparently favorable results. Unfortunately,
Alexander and Fisher [46] used a historical control
group. Thus their results should be viewedwith cau-
tion. Jones et al. [47] studied patients in a hospital
in India. Topical administration of antibacterial
agents was not used, patients were not placed in a
protective environment, and the antibiotics used for
treating infections were ampicillin and penicillin.
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Thus there is a question of the relevance of this non-
blinded study to burned patients in Western Europe
and North America.
There have been no reports of clinical trials in
which either standard or hyperimmune IVIG prepa-
rations were administered to burned patients for
therapeutic or prophylactic purposes. Standard and
R aeruginosa-hyperimmune IVIG preparations have
shown good immunologic and opsonic activity in
vitro and were protective in animal experiments
[48-51]. In a preliminary report Shirani et al. [52]
described the maintenance of normal serum IgG lev-
els in burned patients by the infusion of 500 mg
IVIG/kg twice a week.
Postsurgical and trauma patients. Prophylactic
use of IVIG. There have been two trials of IVIG
for prophylaxis in patients after surgery or trauma
[53, 54]. Duswald et al. in Germany [53] studied
~-propiolactone-treated IVIG. They randomized, in
a nonblinded fashion, 150patients who had under-
gone elective abdominal or thoracic surgery into
three groups: a control group receiving no immuno-
globulin, a group receiving a low dose of IVIG (2.5
g after surgery), and a group receiving a high dose
of IVIG (10 g after surgery and 10 g the following
day). These investigators further divided the patients
into low-risk (following clean and clean-contami-
nated operations) and high-risk (following contami-
nated and dirty operations) groups. A decrease in
the number of local infections in the low-risk group
of patients was observed after high-dose IVIG (six
of 28 patients developed local infections in the high-
dose IVIG group, compared with 15of 29 in the low-
dose and 15of 33 in the control groups). No differ-
ence in the incidence of local infections was seen
among high-risk patients. In the patients with in-
fections lasting for more than 14 days, the authors
reported a significant decrease in the incidence of
"systemic repercussions" of the focal infections, an
ill-defined condition. Unfortunately, this study suf-
fers from deficiencies, such as the absence of blind
evaluation of outcome, the lack of microbiologic
documentation of infections, and the unreported
death rate; thus a strict evaluation of the results is
difficult.
Glinz et al. in Switzerland [54] performed' a
double-blind randomized study in which 150severely
injured patients received either very high doses of
a pH 4-treated IVIG preparation (36g in three equal
doses administered on days 0, 5, and 12after trauma)
or the same volume of a placebo (0.03% albumin
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solution). The two groups werewellbalanced for pa-
tient characteristics and injury-severity scores. The
occurrence of septicemia and local infections was
similar except for a lower incidence of pneumonia
in the IVIG group (28 cases) compared with the pla-
cebo group (43 cases). The bacteriologic documen-
tation of pneumonia was insufficient, however, and
the clinical and radiologic severity of the pneumonic
episodes was not reported. The decrease in the inci-
dence of pneumonia in the IVIG group did not ap-
pear to have a major impact on clinical outcome,
since the number of days with ventilatory assistance,
the overall lethality, and the lethality caused by in-
fections were not decreased. A possible benefit of
IVIG wasthat IVIG-treated patients seemed to need
antibiotics less often than control patients. The du-
ration of stay in the intensive care unit was not ana-
lyzed. Thus, no major impact of high-dose IVIG
given prophylactically was observed in this study of
critically injured patients.
Postsurgical and traumapatients- therapeutic use
ofIVIG. Just et al. [55] have tested an IVIG prep-
aration containing a mixture of IgG (30mg/ml), IgM
(5 mg/mI) , and IgA (7.8 mg/mI). The method of
preparation of this antibody mixture was not de-
scribed. One hundred four infected postoperative pa-
tients in an intensive care unit were randomized in
a nonblinded manner to receive either antibiotics
combined with IVIG (100 ml four times within 36
hr) or antibiotics alone. The patients were entered
into four different risk groups according to a
preoperative classification established by the authors.
The commonest infections observed during the study
were pneumonia, septicemia, peritonitis, and wound
sepsis. The diagnoses werewellbalanced between the
two treatment groups, but the severity of the infec-
tions was not described. Differences in the microor-
ganisms recovered from the infected sites were ap-
parent between the two treatment groups; E. coliand
Haemophilusinfluenzaewerecommoner in the IVIG
treatment group, while S. aureus, P. aeruginosa, En-
terobactercloacae, and other gram-negative bacte-
ria were commoner in the control group. The mor-
tality attributed to infections and the overall
mortality did not differ between the IVIG and the
control groups (seven of 50 vs. 11 of 54 and 25 of
50 vs. 22 of 54, respectively). In patients preopera-
tively classified as high risk, the durations of respi-
ratory support and stay in the intensivecare unit were
significantly shorter in the IVIG treatment group
than in controls (5.5 vs. 12.7 days and 14.8vs. 21.5
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days, respectively). These differences werenot found
in the three other categories of surgical-risk groups.
The beneficial effect of IVIG observed in this study
needs confirmation in a double-blind trial mainly
because the major impact of IVIG in that study was
on the duration of stay in the intensive care unit, a
criterion that may be biased by the knowledge of the
treatment group.
Conclusions: Use of IVIG in the Critically III Patient
The clinicaltrials reported abovedid not demonstrate
serious adverse effects of the administration of IVIG
to neonates as well as to burned, postsurgical, and
trauma patients. In vitro and animal experiments
have shown a protective efficacy of IVIG prepara-
tions against various bacterial infections. Unfortu-
nately, the results of trials in humans that are
presently available are subject to criticism because
of problems in study designs. Overall, the benefits
reported were moderate. No major impact on mor-
tality has been observed. Further well-designed
studies are needed to investigatethe cost-effectiveness
of IVIG administration to critically ill patients. This
question is important since IVIG preparations are
very expensiveand many patients are candidates for
receiving them. Currently, the role of IVIG in the
management of critically ill patients is still largely
ignored.
Clinical Studies of Core-Glycolipid Antiserum or
Plasma for Treatment and Prophylaxis of
Gram-Negative Bacteremia
As mentioned earlier the poor outcome of gram-
negative bacterial infections in humans is attributed
to the LPS, the toxicity of which is not prevented
by antibiotics. Studies in animals have shown that
immunization with smooth gram-negative bacteria
protects from many of the adverse effects of en-
dotoxin and gram-negative bacterial infections [56,
57]. However, antibodies to complete LPS are
directed primarily against the immunodominant,
species-specificoligosaccharide side chains and pro-
tect mainly against the immunizing bacterial strain.
Since thousands of antigenically different strains
may cause infections in humans, it is difficult to ob-
tain broadly protective antibodies to a mixture of
side chains.
In contrast to oligosaccharide side chains, the cen-
tral part of the LPS molecule - the core glycolipid,
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which is responsible for LPS toxicity - shows little
strain variation. Immunization with bacteria whose
LPS contains only core-glycolipid determinants,
such as various rough mutants of gram-negative bac-
teria, has been shown to protect animals from a wide
variety of gram-negative bacteria [58-63] and en-
dotoxins [64-66]. In addition, as previously men-
tioned, retrospective studies in humans have shown
that levels of antibody to core glycolipid correlated
with survival of patients from bacteremia due to var-
ious gram-negative bacilli [8, 11] and to P. aerugi-
nosa [10]. These observations in animals and humans
have prompted clinical studies with antiserum ob-
tained by immunizing volunteers with the rough mu-
tant E. coli J5. This preparation has been tested in
double-blind, randomized, controlled trials for ther-
apy in patients with established gram-negative bac-
teremia and for prophylaxis against gram-negative
bacillary infections in high-risk surgical patients.
Treatment ofgram-negative bacteremia. Ziegler
et al. [67]have studied the cross-protection afforded
by antisera collected from humans after immuniza-
tion with E. coli J5. Serum was withdrawn from
healthy volunteers before (control serum) and two
weeks after immunization with J5 vaccine (J5 an-
tiserum). In a randomized double-blind trial, these
investigators administered test serum to 304patients
with clinically suspected severe gram-negative bac-
teremia. The diagnosis was subsequently confirmed
microbiologically in 212patients (70010); 109of these
patients received control serum and 103receivedim-
mune serum. Characteristics of patients such as age,
sex, race, severity of underlying diseases, and treat-
ments received were well balanced between the two
groups. Also well balanced were conditions with a
poor prognosis, such as gram-negative bacillary
pneumonia, pseudomonas bacteremia, hypotension,
or profound septic shock. The most frequent sources
of bacteremia were abdominal infections (33 inthe
control group and 27 in the J5 group), neutropenia
(41 and 29, respectively), soft tissue and mucous
membrane infections (25and 23),pneumonia (15 and
15), and genitourinary tract infections (18 and 14).
The most frequent bacterial isolates wereE. coli (35
and 35, respectively), P.aeruginosa (20 and 24), and
Klebsiella species (16and 13).The number of deaths
in the bacteremic patients was 42 (39010) of 109 in
controls and 23 (22%) of 103 in recipients of J5 an-
tiserum (P = .011). In those patients with profound
shock who needed treatment with vasopressors for
more than six hours, mortality was reduced from 30
Baumgartner and Glauser
(77010) of 39 in controls to 18(44010) of 41 in recipients
of J5 antiserum (P = .003). The protection afforded
by J5 antiserum was the most striking in neutrope-
nia and soft tissue infections, and was less apparent
in abdominal infections, in which the mortality rate
was 39010 in controls and 33010 in recipients of J5 an-
tiserum.
Overall, this study established that the adminis-
tration of J5 antiserum decreased the mortality rate
by one-half in patients with established gram-
negative bacteremia, even when profound septic
shock was already present.
Prophylaxis ofgram-negative bacillary shock in
surgicalpatients. In view of the success of J5 anti-
serum in the treatment of patients with established
gram-negative bacteremia or shock, a randomized,
double-blind trial of plasma containing antibodies
to J5 (anti-J5 plasma) for prophylaxis was performed
in surgical patients at high risk of acquiring gram-
negative bacterial infections [68]. Since J5 antiserum
had apparently not improved the survival of patients
with gram-negative bacteremia originating from ab-
dominal infections in the therapeutic trial, a major
purpose of the trial for prophylaxis was to test
whether anti-J5 plasma would prevent the establish-
ment of gram-negative bacteremia in patients under-
going complicated abdominal surgery, a condition
with a high risk of severegram-negative bacillary in-
fections. The other purpose of this trial was to test
the prophylactic efficacy of anti-J5 plasma in other
surgical injuries with a high incidence of infectious
complications, such as severe multiple trauma and
pulmonary surgery in high-risk patients. Immuni-
zation of volunteers was performed as in the previ-
ous study, but plasma was used instead of serum be-
cause plasmapheresis allowed the collection of larger
volumes from the volunteers. Patients suitable for
the study were randomized separately in each cate-
gory of surgery. Each patient received one unit of
test plasma (4 ml/kg) during the first 24 hr after ad-
mission to the surgical intensive care unit and booster
units every five days as long as the patient remained
severely ill in the intensive care unit. Additional test
plasma was given if septic shock developed because
it was hypothesized that antibodies to core glycolipid
might be depleted in this condition.'
Two hundred sixty-two patients were included in
the study and observed daily aslong as they remained
in the intensive care unit and for two weeks there-
after. The analysis of the results showed that anti-J 5
plasma did not prevent the acquisition of new focal
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gram-negative bacterial infections, nor did it prevent
shaking chills and febrile spikes associated with such
infections. In contrast, anti-15 plasma was very ef-
fective in preventing the severe consequences of
gram-negative bacterial infections, i.e., shock and
death. This protective effect was most striking in pa-
tients who had undergone abdominal surgery, in
whom the majority of the severegram-negative bacil-
lary infections occurred during the study. Indeed,
among this latter category of patients, shock oc-
curred in 13 of 83 control-plasma recipients and in
only two of 71 anti-15-plasma recipients (P = .006),
and subsequent death occurred in nine of 83 and one
of 71 (P = .017), respectively (table 4). In the two
other surgical categories, fewer severe gram-negative
bacterial infections occurred, and the efficacy of
anti-15 plasma was not demonstrable separately in
each category. When all categories of patients were
considered together, the protection was significant:
gram-negative bacillary shock occurred in 15of 136
control-plasma recipients and in six of 126 anti-15-
plasma recipients (P = .049) and subsequent death
occurred in nine of 136 and two of 126 patients,
respectively (P = .033). Very striking was that the
incidences of shock and death due to gram-positive
bacteria or fungi were not different between the two
study groups, an observation demonstrating that the
effect of anti-15 plasma was specifically directed
against gram-negative bacteria.
The results of this clinical study strengthen, there-
fore, those of previous studies in animals on the
mode of action of antibodies to core glycolipids. The
latter studies have suggested that such antibodies
may act primarily as neutralizing (antitoxic) antibod-
ies, not as opsonizing antibodies [69]. Indeed, anti-
15 plasma in our study did not prevent the acquisi-
tion of new gram-negative bacterial infections; it only
prevented their toxic consequences.
Discussion andfuture areas a/research. The cur-
rent view on the mechanism of protection afforded
by 15 antiserum or anti-15 plasma is that they neu-
tralize the harmful effects of endotoxins by means
of cross-reactive antibodies to core glycolipid. This
view is supported by previous animal experiments
showing cross-protection from 15 antiserum not
only against whole gram-negative bacteria but also
against purified endotoxins [59-66]. Furthermore,
the results of retrospective studies in humans have
demonstrated a significant correlation between titers
of antibody to core glycolipid and survival of pa-
tients with bacteremia due to various gram-negative
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Table 4. Prevention of shock and death due to gram-
negative bacteria with anti-J5 plasma administered pro-
phylactically to surgical patients at high risk of infection.
No. of patients
receiving indicated
Category of surgery,
type of plasma
outcome Control Anti-J5 P value
Abdominal 83 71
Infection" 21 15 NS
Shock 13 2 .006
Death 9 1 .017
All categories t 136 126
Infection* 33 29 NS
Shock 15 6 .049
Death 9 2 .033
NOTE. Adapted from [68]. Abbreviation: NS = not
significant.
* Infections were pneumonia and intraabdominal and media-
stinal infections.
t The categories of surgery other than abdominal surgery
were: multiple trauma (31 patients in control and 34 in anti-J5
group) and pulmonary surgery in high-risk patients (22 patients
in control and 21 patients in anti-J5 group).
bacilli (table 2), and P. aeruginosa (table 3). Lastly,
in the prospective studies reported above, 15 antise-
rum and anti-15 plasma have been shown to improve
survival of patients with established gram-negative
bacteremia [67] and specifically to prevent the oc-
currence of septic shock and death due to gram-neg-
ative, but not gram-positive, bacteria [68].
Such a mechanism of cross-protection has not
been definitely proved in clinical trials, however. In-
deed, in the trials of 15 antiserum for both therapeu-
tic and prophylactic use, it has been difficult, for
several reasons, to clearly relate outcome with levels
of antibody to core glycolipid. The first reason is
that many sera from nonimmunized volunteers as
well as sera from recipientpatients had naturally oc-
curring antibodies to 15 LPS, sometimes in very high
titers. The second reason is that 15 vaccine is a weak
immunogen and, in volunteers, induced only a three-
to five-fold increase in titers of antibody to 15 LPS
([67] and authors' unpublished data). For these two
reasons there has been a great overlap in titers of an-
tibody to 15 LPS between immune and control se-
rum (or plasma) administered to patients. The third
reason is that the administration of 4 ml of immune
plasma/kg to the patients in the prophylactic trial
produced only a slight, sometimes undetectable, in-
crease in levels of antibody to 15 LPS (authors' un-
published data).
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For these reasons, although the clinical data clearly
showed a benefit from the administration of J5 anti-
serum or anti-J5 plasma as compared with a similar
volume of the nonimmune preparation, the relation
between levels of antibody to J5 LPS administered
to the patients and improvedoutcome has been weak.
Indeed, Ziegler et al. [67] measured antibodies to J5
LPS by indirect hemagglutination. Overall, they
could not relate protection to titers in antiserum ad-
ministered, regardless of the immunologic status of
the donor. They could only show a protective trend
with respect to J5-antibody titers in patients in pro-
found gram-negative bacterial shock. In this group
the mortality rate in 53 patients given serum with
hemagglutinating antibody titers of >1:8 was 53070,
as compared with 74% in 27 patients given serum
with titers of ~1:8 (P = .07).
In the study of prophylactic use of anti-J5 plasma
in surgical patients [68], a correlation was found be-
tween the number of deaths due to gram-negative
bacillary infections and levels of IgG or IgM anti-
body to J5 LPS in plasma administered to the pa-
tients (table 5). However, a multivariate analysis
demonstrated that the best predictor of the protec-
tive power of the plasma was not the levels of IgG
or IgM antibodies to J5 LPS present in the plasma,
but whether the plasma was from immune or con-
trol volunteers (authors' unpublished data). Thus,
both prospective trials have not convincinglydemon-
strated that the protective activity of J5 antiserum
or anti-J5 plasma was due to antibodies to J5 LPS,
as measured by ELISA or indirect hemagglutination.
At the present time, in addition to the hypothesis
attributing cross-protection to antibodies to J5 LPS,
three alternatives might be proposed to explain the
beneficial effects of immunization by heat-killed
E. coli J5 cells. The first is that protection might be
mediated by humoral factors other than antibody.
The J5 vaccine may nonspecifically increase some
unrecognized acute-phase reactants capable of neu-
tralizing LPS or altering its metabolism [70-72]. The
second possibility is that passive protection, as seen
after immunization with E. coli J5, might be due to
a nonspecific polyclonal antibody response of the
immunized volunteers, a phenomenon known to oc-
cur after injections of endotoxins from both smooth
and rough bacteria [73, 74]. To investigate this hy-
pothesis, we tested 12pairs of human plasma, sam-
pled before and after immunization with J5 vaccine,
against LPSs extracted from seven unrelated smooth
gram-negative bacteria. A modest polyclonal in-
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Table 5. Relation of death due to infections with gram-
negative bacteria to levels of antibody to J5 lipopoly-
saccharide (LPS) in plasma administered prophylactically
to surgical patients.
Level of antibody" No. of No. of
(units/ml) patients deaths P value
IgG antibody to J5 LPS
~50 133 8
.057t
>50 129 2
IgM antibody to J5 LPS
~50 183 10
.02t
>50 71 0
• Measured by ELISA.
t A multivariate analysis revealed that whether the plasma was
immune or control was a better predictor of outcome than the
levels of antibody to J5 lipopolysaccharide (IgG or IgM).
crease of IgG and/or IgM antibodies was observed
in only eight of the pairs. In these pairs the mean
increase in titers of antibody against the seven
smooth LPSs ranged from l.1-fold to 2.2-fold (M.
Pollack and J.D. Baumgartner, unpublished data).
This increase seems modest if it is to fully account
for the broad protection afforded by plasma after
immunization with E. coli J5. Furthermore, if either
one or both of the two mechanisms mentioned above
were operative in the protection afforded after ad-
ministration of anti-J5 plasma, it would not account
for the experimental observation that only very
limited cross-protection is observed after immuni-
zation with smooth bacteria.
A third, more likely explanation is that protection
might be due to cross-reactive antibodies to core
glycolipid that are not accurately measured when
using J5 LPS as the test antigen. To investigate this
latter possibility, we immunized rabbits with E. coli
J5 and then examined the reactivity of the rabbit se-
rum against various strains of gram-negative bacte-
ria. Adsorption of highly diluted rabbit J5 antise-
rum with various smooth, gram-negative bacteria
reduced by <35% the levels of antibody to J5 LPS
measured by ELISA [75]. This decrease demon-
strated that most antibodies to J5 LPS weredirected
against determinants that are specific for the J5 LPS
molecule and presumably associated with core sug-
ars. When we measured antibody to S. minnesota
Re LPS, which in contrast to J5 LPS contains no
core structures other than lipid A and 2-keto-3-de-
oxyoctonate (KDO), we found, by adsorption with
S. minnesota Re or by direct ELISA, that <5070 of
the total antibodies to J5 LPS was directed against
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Re LPS in serum from rabbits immunized with
E. coli 15. This might not, however, reflect the ac-
tual proportion of antibodies to lipid A and KDO
since antibody directed against lipid determinants
might have a lower affinity than antibody directed
against oligosaccharides of the core, thus prevent-
ing the detection of the former by ELISA. Further
studies are needed to determine precisely which epi-
tope(s) (possibly the lipid A or part of it) on the com-
plex 15 LPS molecule may be responsible for elicit-
ing cross-protective antibody.
In summary, if protection afforded by serum or
plasma collected from volunteers after immuniza-
tion with E. coli 15 is mediated by cross-protective
antibodies to LPS, two important questions remain
to be definitively answered. One is the determina-
tion of the epitope(s) of the LPS core molecule that
is the relevant antigen(s) for eliciting the best cross-
reactive antibodies. The answer to this question is
crucial at the present time because it will permit the
screening of blood donors for the preparation of
hyperimmune purified immunoglobulins, as well as
the production of monoclonal antibodies. The sec-
ond question still unresolved is which type of anti-
bodies - IgG, IgM, or both - is most protective. The
resolution of this question is important if hyperirn-
mune IVIG preparations must be used, since these
preparations contain almost exclusively IgG. Only
after the resolution of these two questions will it be
possible to test, in well-controlled clinical trials, the
efficacies of hyperimmune IVIG preparations and
monoclonal antibodies in the treatment of critically
ill patients.
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